PZ0207

PF-04620110

≥98% (HPLC)

• Synonym(e): trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid
• Empirische Formel (Hill-System): C₂₁H₂₄N₄O₄
• CAS-Nummer: 1109276-89-2
• Molekulargewicht: 396.44
• UNSPSC-Code: 12352202
• PubChem Substanz-ID: 329823775
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 10 mg/mL (clear solution)
• Lagertemp.: room temp
• SMILES String: Nc1ncnc2OCCN(C(=O)c12)c3ccc(cc3)[C@@H]4CC[C@H](CC4)CC(O)=O
• InChI: 1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)/t13-,14-
• InChIKey: GEVVQZHMFVFGLN-HDJSIYSDSA-N

Beschreibung

Biochem./physiol. Wirkung

PF-04620110 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that inhibits triacylglycerol synthesis in cells and in rodents.

PF-04620110 is known to regulate gut hormones. Inhibition of DGAT1 might serve as a good approach for the treatment of obesity and type 2 diabetes. DGAT1 inhibition might increase the oxidation of fatty acids, thus it is found to be protective against hepatic steatosis.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H302
• P-Sätze: P264 - P270 - P301 + P312 - P501
• Gefahreneinstufungen: Acute Tox. 4 Oral
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable